Literature DB >> 12808353

Attenuation of canine cerebral vasospasm after subarachnoid hemorrhage by protein kinase C inhibitors despite augmented phosphorylation of myosin light chain.

Shigeru Nishizawa1, Kazuo Obara, Masayo Koide, Koichi Nakayama, Seiji Ohta, Tetsuo Yokoyama.   

Abstract

The purpose of the present study is to assess the roles of protein kinase C (PKC) isoforms, especially PKC delta and alpha, and 20-kD myosin light chain (MLC(20)) phosphorylation in the mechanism of cerebral vasospasm following subarachnoid hemorrhage (SAH). We had shown that those PKC isoforms are involved in the development of cerebral vasospasm. Using PKC isoform-specific inhibitors in a 'two- hemorrhage' canine model, we examined changes in the development of cerebral vasospasm, translocation of PKC isoforms and MLC(20) phosphorylation level in canine basilar arteries. A PKC inhibitor (5 microM rottlerin for PKC delta or chelerythrine for PKC alpha) was injected into the cisterna magna on day 4 before the second hemorrhage. The treatment was continued daily until day 7. Rottlerin inhibited the initial phase of vasospasm and PKC delta translocation, but did not significantly inhibit PKC alpha translocation. Chelerythrine inhibited cerebral vasospasm, and the translocation of both PKC delta and alpha throughout the entire course of the study. Although cerebral vasospasm after SAH was inhibited by each PKC inhibitor, the MLC(20) phosphorylation level remained elevated as in the untreated hemorrhage-control study. We conclude that cerebral vasospasm following SAH depends on PKC delta and alpha, while the enhancement of MLC(20) phosphorylation contributes little to this form of vasospasm. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12808353     DOI: 10.1159/000070714

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  6 in total

Review 1.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

Review 2.  Cerebral vasospasm: a consideration of the various cellular mechanisms involved in the pathophysiology.

Authors:  Jacob Hansen-Schwartz
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

3.  Targeted over-expression of endothelin-1 in astrocytes leads to more severe brain damage and vasospasm after subarachnoid hemorrhage.

Authors:  Patrick K K Yeung; Jiangang Shen; Stephen S M Chung; Sookja K Chung
Journal:  BMC Neurosci       Date:  2013-10-25       Impact factor: 3.288

4.  Alteration of basilar artery rho-kinase and soluble guanylyl cyclase protein expression in a rat model of cerebral vasospasm following subarachnoid hemorrhage.

Authors:  Chih-Jen Wang; Pei-Yu Lee; Bin-Nan Wu; Shu-Chuan Wu; Joon-Khim Loh; Hung-Pei Tsai; Chia-Li Chung; Neal F Kassell; Aij-Lie Kwan
Journal:  Biomed Res Int       Date:  2014-06-01       Impact factor: 3.411

5.  Calcium and potassium channels in experimental subarachnoid hemorrhage and transient global ischemia.

Authors:  Marcel A Kamp; Maxine Dibué; Toni Schneider; Hans-Jakob Steiger; Daniel Hänggi
Journal:  Stroke Res Treat       Date:  2012-12-09

Review 6.  Therapeutic potential of chelerythrine as a multi-purpose adjuvant for the treatment of COVID-19.

Authors:  Mehdi Valipour; Afshin Zarghi; Mohammad Ali Ebrahimzadeh; Hamid Irannejad
Journal:  Cell Cycle       Date:  2021-09-29       Impact factor: 4.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.